Oral drugs for advanced or multiple basal cell skin cancer
Treatments studied
Part of Bones, joints & muscles, Cancer, Genetic & congenital, Mouth & dental, Skin clinical trials.
This study registers people in the Netherlands who have certain types of basal cell skin cancer and take an oral hedgehog-blocking medicine. It may help doctors understand how well these tablets work and how patients do in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with basal cell skin cancer that is locally advanced, metastatic, or involves multiple tumors, or you have Gorlin syndrome
- You are planning to take (or already taking) the oral drug vismodegib
- You are planning to take (or already taking) the oral drug sonidegib
- You can be any age (men or women are both eligible)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at using a medication that blocks the “Sonic Hedgehog” pathway together with radiotherapy to reduce future problems from locally advanced basal cell carcinoma (BCC). It’s for people whose cancer responded completely to the first Sonic Hedgehog pathway inhibitor treatment and where doctors can confirm that response with a tissue test.
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This study looks at how people with advanced basal cell carcinoma (a type of skin cancer that is hard to treat or has spread) are cared for and what happens over time. It does not test any new treatments, but helps doctors learn more about the disease.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
Hear when a new Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.